Skip to main content
LUSHANG FREDA PHARMACEUTICAL CO.,LTD. logo

LUSHANG FREDA PHARMACEUTICAL CO.,LTD. — Investor Relations & Filings

Ticker · 600223 ISIN · CNE000001147 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,828 across all filing types
Latest filing 2025-03-21 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 600223

About LUSHANG FREDA PHARMACEUTICAL CO.,LTD.

http://www.lshfreda.com/

Lushang Freda Pharmaceutical Co., Ltd. specializes in the research, development, and manufacturing of pharmaceutical products, health supplements, and high-end cosmetics. The company is recognized as a global leader in the production of sodium hyaluronate (hyaluronic acid), utilizing advanced fermentation technology to supply raw materials for medical, food, and cosmetic applications. Its product portfolio spans several therapeutic areas, including ophthalmology, orthopedics, and dermatology, with a significant focus on medical aesthetics and functional skincare. By integrating biotechnology with industrial-scale production, the company maintains a comprehensive supply chain that supports both its proprietary brands and international B2B partnerships. Key operations involve the synthesis of bioactive substances and the formulation of specialized treatments designed to improve skin health and joint mobility.

Recent filings

Filing Released Lang Actions
鲁商福瑞达医药股份有限公司关于控股下属公司山东蓝岸园林工程有限公司拟增资扩股及公司放弃等比例优先认购权暨关联交易的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding a related-party transaction involving the company's controlled subsidiary and a capital increase by an affiliated party. It includes information about the transaction structure, parties involved, valuation, board approval, and impact on the company's consolidated financial statements. There is no indication that this is a full financial report, earnings release, or regulatory certification. The content focuses on a capital/financing update related to equity ownership changes and a waiver of preemptive rights, which fits the Capital/Financing Update category. The document length and detail confirm it is not a brief announcement or a report publication notice.
2025-03-21 Chinese
鲁商福瑞达医药股份有限公司2024年度独立董事述职报告（朱德胜）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Annual Report" for the year 2024 by an independent director of the company. It details the director's activities, attendance at board and committee meetings, opinions on financial reports, internal controls, related party transactions, and governance matters throughout the year. The content focuses on the independent director's duties, oversight, and evaluations rather than presenting full financial statements or audit results. It is a specialized report on board/management information, specifically the independent director's annual work report. It is not an annual report (10-K), audit report (AR), or other financial filings. Therefore, the document fits best under Board/Management Information (MANG). The document length (9207 characters) and detailed content support this classification with high confidence.
2025-03-21 Chinese
鲁商福瑞达医药股份有限公司关于2024年第四季度主要经营数据的公告
Regulatory Filings Classification · 95% confidence The document is titled as an announcement regarding the company's main operating data for the fourth quarter of 2024. It contains detailed quantitative data on production volume, sales volume, revenue, and price changes for products and raw materials for the specified quarter. The document is relatively short (1458 characters) and focuses on operational data rather than comprehensive financial statements or management discussion. It is not a full interim or quarterly report (IR) because it lacks substantive financial statements or detailed financial analysis. Instead, it is a quarterly operating data announcement, which typically falls under the category of Regulatory Filings (RNS) as it is a regulatory disclosure of operational metrics without full financial reporting. Therefore, the appropriate classification is Regulatory Filings (RNS).
2025-03-21 Chinese
鲁商福瑞达医药股份有限公司第十二届董事会独立董事专门会议决议
Board/Management Information Classification · 95% confidence The document is a resolution from the independent directors of the company's board regarding various corporate governance matters, including approval of related party transactions, financial service agreements, risk assessment reports, and capital increase decisions. It is a formal board/management announcement about internal governance and decision-making processes. There is no financial statement or detailed financial report content, nor is it an announcement of a report publication. The document fits best under Board/Management Information (MANG) as it concerns board resolutions and management decisions.
2025-03-21 Chinese
鲁商福瑞达医药股份有限公司关于在山东省商业集团财务有限公司开展金融业务的风险处置预案
Regulatory Filings Classification · 95% confidence The document is a detailed risk management plan related to financial business activities between the company and a financial entity. It outlines risk types, monitoring, emergency procedures, and governance related to financial risks. It is not a financial report, earnings release, or regulatory filing announcement. It is a formal internal policy or risk management document approved by the board. There is no indication it is an audit report, annual report, or any other financial statement. It is also not a notice of voting results, capital change, or legal proceeding. The document is best classified as a Regulatory Filing (RNS) because it is a compliance-related risk management disclosure that does not fit other specific categories.
2025-03-21 Chinese
鲁商福瑞达医药股份有限公司董事会关于2024年度独立董事独立性情况的专项报告
Board/Management Information Classification · 95% confidence The document is a special report from the board of directors regarding the independence of the company's independent directors for the year 2024. It references regulatory requirements related to independent directors and their independence evaluation. The content is focused on governance and compliance with listing rules, specifically about board members' independence. It does not contain financial data, audit results, or voting results. It is a governance-related report about board/management information rather than a general governance framework or rules document. Therefore, the most appropriate classification is Board/Management Information (MANG). The document length is short but contains substantive content about board members' independence, not just an announcement or certification, so it is not RNS or RPA.
2025-03-21 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.